GlassScriptPhysician profile
Martin E Goldman
NPI 1497853063
$123,179.15
in general payments reported to CMS, 2019-2025
11 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $20K · 2021: $5,539 · 2022: $22K · 2023: $28K · 2024: $13.76 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $2,353 · Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,450.00 |
| Travel and Lodging | $2,352.60 |
| Food and Beverage | $776.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $122,225.76 | 2019-2025 | Definity |
| Janssen Pharmaceuticals, INC | $438.84 | 2021-2023 | Xarelto |
| Abbott Laboratories | $218.29 | 2019-2023 | Mitraclip |
| Philips North America LLC | $102.25 | 2022 | |
| Novo Nordisk INC | $79.71 | 2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $33.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.85 | 2023 | Camzyos |
| Heartflow, INC. | $25.37 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals International, Plc | $13.76 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $12.79 | 2023 | Zio Xt Patch |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.